147
Views
1
CrossRef citations to date
0
Altmetric
Articles

Value of silicone gel in prevention of cobblestoning following punch minigrafting in vitiligo

, , , , , & show all
Pages 306-313 | Received 26 Jan 2020, Accepted 28 Mar 2020, Published online: 13 Apr 2020

References

  • Dillon AB, Sideris A, Hadi A, et al. Advances in vitiligo: an update on medical and surgical treatments. J Clin Aesthet Dermatol. 2017;10(1):15–28.
  • Lahiri K. Evolution and evaluation of autologous mini punch grafting in vitiligo. Indian J Dermatol. 2009;54(2):159–167.
  • Njoo MD, Westerhof W, Bos JD, et al. A systematic review of autologous transplantation methods in vitiligo. Arch Dermatol. 1998;134(12):1543–1549.
  • Agarwal US, Jain D, Gulati R, et al. Silicone gel sheet dressings for prevention of post-minigraft cobblestoning in vitiligo. Dermatol Surg. 1999;25(2):102–104.
  • Komen L, Vrijman C, Prinsen C, et al. Optimising size and depth of punch grafts in autologous transplantation of vitiligo and piebaldism: a randomized controlled trial. J Dermatolog Treat. 2017;28(1):86–91.
  • Gupta S, Honda S, Kumar B. A novel scoring system for evaluation of results of autologous transplantation methods in vitiligo. Indian J Dermatol Venereol Leperol. 2002;68:33–37.
  • Puri N, Talwar A. The efficacy of silicone gel for the treatment of hypertrophic scars and keloids. J Cutan Aesthet Surg. 2009; 2(2):104–106.
  • Trojanowska M. Ets factors and regulation of the extracellular matrix. Oncogene. 2000;19(55):6464–6471.
  • Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999;274(31):21491–21494.
  • Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 2003;92(8):827–839.
  • Midwood KS, Chiquet M, Tucker RP, et al. Tenascin-C at a glance. J Cell Sci. 2016;129(23):4321–4327.
  • Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol. 2008;84(3):623–630.
  • Njoo MD, Das PK, Bos JD, et al. Association of the Koebner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol. 1999;135(4):407–413.
  • Leheta T, El Garem Y, Hegazy R, et al. Non-ablative 1540 fractional laser: how far could it help injection lipolysis and dermal fillers in lower-face rejuvenation? A randomized controlled trail. J Cosmet Laser Ther. 2013;15(1):13–20.
  • Berman B, Maderal A, Raphael B. Keloids and hypertrophic scars: pathophysiology, classification, and treatment. Dermatol Surg. 2017;43(Suppl 1):S3–S18.
  • Ghazawi FM, Zargham R, Gilardino MS, et al. Insights into the Pathophysiology of Hypertrophic Scars and Keloids: How Do They Differ? Adv Skin Wound Care. 2018; 31(1):582–595.
  • Chan KY, Lau CL, Adeeb SM, et al. A randomized, placebo-controlled, double-blind, prospective clinical trial of silicone gel in prevention of hypertrophic scar development in median sternotomy wound. Plast Reconstr Surg. 2005; 116(4):1013–1020. discussion 1021–2.
  • Chittoria RK, Padi TR. A prospective, randomized, placebo controlled, double blind study of silicone gel in prevention of hypertrophic scar at donor site of skin grafting. J Cutan Aesthet Surg. 2013; 6(1):12–16.
  • Kim SM, Choi JS, Lee JH, et al. Prevention of postsurgical scars: comparsion of efficacy and convenience between silicone gel sheet and topical silicone gel. J Korean Med Sci. 2014;29(Suppl 3):S249–S53.
  • Kumar R, Parsad D, Kanwar AJ, et al. Altered levels of Ets-1 transcription factor and matrix metalloproteinases in melanocytes from patients with vitiligo. Br J Dermatol. 2011; 165(2):285–291.
  • Lee DE, Trowbridge RM, Ayoub NT, et al. High-mobility group box protein-1, matrix metalloproteinases, and vitamin D in keloids and hypertrophic scars. Plast Reconstr Surg Glob Open. 2015; 8(3(6):e425.
  • Neely AN, Clendening CE, Gardner J, et al. Gelatinase activity in keloids and hypertrophic scars. Wound Repair Regen. 1999; 7(3):166–171.
  • El Mofty M, Esmat S, Hunter N, et al. Effect of different types of therapeutic trauma on vitiligo lesions. Dermatol Ther. 2017;30(2):e12447.
  • Le Poole IC, Van den Wijngaard RM, Westerhof W, et al. Tenascin is overexpressed in vitiligo lesional skin and inhibit melanocyte adhesion. Br J Dermatol. 1997; 137(2):171–178.
  • Abdou AG, Maraee AH, Shoeib MA, et al. Immunolocalization of Tenascin-C in vitiligo. Appl Immunohistochem Mol Morphol. 2012; 20(5):501–511.
  • Laddha NC, Dwivedi M, Begum R. Increased tumor necrosis factor (TNF)-α and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo. PLoS One. 2012;7(12):e52298.
  • Karam RA, Zidan HE, Khater MH. Genetic variants of interferon-gamma and its mRNA expression and inflammatory parameters in the pathogenesis of vitiligo. Biochem Cell Biol. 2017; 95(4):474–481.
  • Latijnhouwers MA, Pfundt R, de Jongh GJ, et al. Tenascin-C expression in human epidermal keratinocytes is regulated by inflammatory cytokines and a stress response pathway. Matrix Biol. 1998;17(4):305–316.
  • Jumper N, Paus R, Bayat A. Functional histopathology of keloid disease. Histol Histopathol. 2015; 30(9):1033–1057.
  • Lieber CS, Weiss DG, Paronetto F, Veterans Affairs Cooperative Study 391 Group. Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcoholism Clin Exp Res. 2008;32(6):1031–1039.
  • Paivaniemi OE, Maasilta PK, Alho HS, et al. Epithelial tenascin predicts obliterative airway disease. J Heart Lung Transplant. 2008;27(4):400–407.
  • Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal. 2009; 3(3-4):287–310.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.